Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-704-4660
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics Inc (NASDAQ:VKTX) posted its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
13 equities research analysts have issued 12-month price targets for Viking Therapeutics' shares. Their predictions range from $8.86 to $40.00. On average, they expect Viking Therapeutics' share price to reach $20.5327 in the next twelve months. This suggests a possible upside of 196.3% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.
What is the consensus analysts' recommendation for Viking Therapeutics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.
What are Wall Street analysts saying about Viking Therapeutics stock?
Here are some recent quotes from research analysts about Viking Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $31 price target. Our peak sales estimates for VK2806 and VK5211 are based on our U.S. projections, and believe overall that peak sales could be conservative because of the size of the addressable markets, the continuing unmet medical need, and no projections for ex-U.S. sales currently. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/2/2019)
- 2. Maxim Group analysts commented, "Viking reported 3Q18 with a net loss of ($6.6M) and ended the period with $304M in cash. We have increased expenses going forward as the NASH program moves into later-stage development and additional programs like 0214 move into the clinic." (11/8/2018)
Has Viking Therapeutics been receiving favorable news coverage?
News headlines about VKTX stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Viking Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Viking Therapeutics.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Zai Lab (ZLAB), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX), Tricida (TCDA), Nabriva Therapeutics (NBRV), Corcept Therapeutics (CORT), Insmed (INSM), Eidos Therapeutics (EIDX), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA) and Ironwood Pharmaceuticals (IRWD).
What other stocks do shareholders of Viking Therapeutics own?
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 53)
- Mr. Michael Morneau, VP of Fin. & Admin. (Age 54)
- Dr. Hiroko Masamune, Chief Devel. Officer (Age 62)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Ms. Marianne Mancini, Sr. VP of Clinical Operations
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Who are Viking Therapeutics' major shareholders?
Viking Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.09%), Vanguard Group Inc. (5.12%), Fiera Capital Corp (1.86%), Northern Trust Corp (1.06%), Sio Capital Management LLC (1.05%) and Bank of America Corp DE (0.76%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.
Which institutional investors are selling Viking Therapeutics stock?
VKTX stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Jane Street Group LLC, LPL Financial LLC, Sio Capital Management LLC, Fiera Capital Corp, Wells Fargo & Company MN, Essex Investment Management Co. LLC and Balyasny Asset Management LLC. View Insider Buying and Selling for Viking Therapeutics.
Which institutional investors are buying Viking Therapeutics stock?
VKTX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Rhenman & Partners Asset Management AB, BlackRock Inc., Nuveen Asset Management LLC, Verition Fund Management LLC, Cubist Systematic Strategies LLC, Artal Group S.A. and Virginia Retirement Systems ET AL. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $6.93.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $500.42 million. The biotechnology company earns $-22,060,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Viking Therapeutics employs 15 workers across the globe.View Additional Information About Viking Therapeutics.
What is Viking Therapeutics' official website?
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
